Please login to the form below

Not currently logged in
Email:
Password:

Lilly to run two Alzheimer's trials

Eli Lilly and Company is to begin enrolling patients in two trials investigating a potential treatment to delay the progression of Alzheimer's

Eli Lilly and Company is to begin enrolling patients in two phase III clinical trials investigating a potential treatment to delay the progression of mild to moderate Alzheimer's disease.

The identical, multi-centred, randomised, double-blind, placebo-controlled trials will enrol a total of 2,000 patients aged over 55, from over 16 countries. The trials, known as Expedition and Expedition 2, will examine solanezumab compared with a placebo over a treatment period of 18 months. Patients will be permitted to continue taking any treatments for the symptoms of the disease during their participation in the trials.

"Current therapies available to treat Alzheimer's disease may help with symptoms, but they haven't been proven to change the disease progression," said Dr Eric Siemers, medical director, Alzheimer's disease research for Eli Lilly and Company. "Biomarker results from a phase II solanezumab trial give us hope that Lilly is on a path towards a treatment that may slow the rate of progression of Alzheimer's disease."

The Expedition trial will be conducted in Argentina, Brazil, Canada, Japan, and United States. Expedition 2 will be conducted in Australia, France, Germany, Italy, Japan, Korea, Poland, Russia, Spain, Sweden, Taiwan, United Kingdom, and United States.

21st May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics